Kornimate/medical-research-clean huggingface dataset:
prednisolone acetate eye drops for pain intervention in second eye cataract surgery

Conditions: Age Related Cataract; Pain Management During Cataract Surgery

Summary: this study aims to evaluate the efficacy, safety, and potential mechanisms of prednisolone acetate eye drops for pain management in patients undergoing second-eye surgery for age-related cataracts. researchers will compare prednisolone acetate eye drops to sodium hyaluronate eye drops to see if prednisolone acetate eye drops work to relieve intraoperative and postoperative pain during second-eye cataract surgery. participants will: 1. receive prednisolone acetate eye drops or sodium hyaluronate eye drop four drops within 2 hours before cataract surgery 2. finish cataract surgery and routine postoperative follow-up 3. pain questionnaire completed after cataract surgery


Eligibility criteria:
inclusion criteria: * age between 50-80 years old; * a clear diagnosis of age-related cataract, having completed the first eye cataract surgery at our hospital, and planning to have the second eye cataract surgery with the same doctor; * the interval between the two surgeries is ≤30 days; * capable of cooperating to complete iris optical coherence tomography angiography examination; * based on our team\&#39;s previous research, a predictive scoring formula for pain during the second eye surgery has been derived (predicted score = 1.36 + 4.93 \* preoperative iris vessel area density - 0.24 \* surgical interval (weeks)), and the calculated predicted score is \&gt;2. exclusion criteria: * history of ocular trauma, ocular surgery, uveitis, fundus disease, glaucoma, or recent history of episcleritis, keratitis, severe dry eye, and other ocular surface disease episodes; * participation in intraocular or systemic medication clinical trials within the past 6 months; * having an autoimmune disease or currently undergoing immunosuppressive therapy; * having a psychiatric disorder such as anxiety or depression; * history of using glucocorticoid eye drops for treatment in the second eye within the past month; * long-term use of drugs that can cause intraoperative floppy iris syndrome, such as alpha-blockers; * severe complications occurred during or after the first eye surgery (e.g., posterior capsule rupture, zonular exercise, nuclear drop into the vitreous cavity, postoperative endophthalmitis, glaucoma, etc.).

Keywords: cataract surgery pain second-eye cataract surgery
increasing access to colorectal cancer testing (iacct) for blacks

Conditions: Colorectal Cancer; Colorectal Carcinoma

Summary: the purpose of this research study is to compare a new educational material to another widely available educational brochure. the goal is to see if the new educational material will change knowledge and behaviors about colorectal cancer and colorectal screening.


Eligibility criteria:
inclusion criteria: * community-based recruitment methods will be used including promotional flyers and word of mouth at locations such as churches, barber shops, civic/community social service centers, senior centers, cultural groups. the flyers will provide brief information and advertise a telephone number for potential participants to call the study office at moffitt. * self identify as black or african american * have no symptoms of colorectal cancer (crc), or personal diagnosis of crc or bowel inflammatory disease or related syndromes * have not had recent crc screening per guidelines (never screened or overdue) * participants must provide at least two forms of contact information (mailing address, home telephone or cell phone or email address), and contact information of a secondary individual who has a number that is different from the participant (this person may be a relative or friend living with the respondent). * spouse or relatives of respondent are potentially eligible. exclusion criteria: * individuals who have participated in a colorectal cancer screening (crcs) research in the past 1 year will not be eligible for this study. * additional criteria may apply.

Keywords: cancer screening
impact of dance therapy on parkinson's disease

Conditions: Parkinson's Disease

Summary: parkinson's disease (pd) affects ability of individuals to perform unconscious learned motor tasks, affects quality of life and has been associated with depression. the purpose of this study is to investigate the effect of dance therapy on motor performance, quality of life and depression in pd patients, by comparing certain symptoms between a group of subjects with pd who undergo ballroom dancing classes and a control group of subjects with pd. the investigators will assess mental status, severity of pd, quality of life and depression using rating scales. subjects will be randomized to intervention and control group. intervention group will participate in dance therapy for 12 weeks and will be examined at 12 and 20 weeks. control group will be examined at same time intervals. classes will follow a curriculum designed by arthur murray dance studio staff. the investigators do not anticipate significant risk for participants.


Eligibility criteria:
inclusion criteria: * 18 years and older, both males and females, all races and all ethnicities * idiopathic parkinson's disease diagnosed using united kingdom parkinson's disease society brain bank diagnostic criteria * mild to moderate disease severity (stage 2 to 3 on the modified hoehn and yahr scale) * stable medication regimen for a minimum of 1 month before testing * ability to ambulate independently without using a walking aid * ability to give informed consent exclusion criteria: * prior enrollment in a dancing class during the last 6 months * presence of another neurological or medical disorder likely to affect gait or causing frequent falls (rheumatologic/orthopedic disease, stroke, myelopathy, severe neuropathy) * significant cognitive decline (mmse ≤ 24) * visual deficit * hearing deficit that impairs music perception * psychotic symptoms * symptomatic heart disease * depression associated with suicidal ideation

Keywords: parkinson ballroom dancing
a study of abatacept in japanese patients with active rheumatoid arthritis while receiving methotrexate

Conditions: Rheumatoid Arthritis

Summary: the purpose of this study is to demonstrate that abatacept combined with methotrexate will demonstrate a dose response efficacy in japanese subjects with active rheumatoid arthritis similar to the dose response efficacy previously observed in the international clinical trials.


Eligibility criteria:
inclusion criteria: * patients with active rheumatoid arthritis while on methotrexate having 12 tender and 10 swollen joints at randomization exclusion criteria: * no current infection or other evolutive or uncontrolled disease
endoscopic retrograde cholangiopancreatography in patients older than 65years old with obstructive jaundice: efficacy and outcome

Conditions: Obstructive Jaundice

Summary: the incidence of pancreato-biliary disorders ,including malignancy, is increasing in elderly patients. endoscopic retrograde cholangiopancreatography (ercp) is a well-known therapeutic tool for these pancreato-biliary disorders. in general, old age is defined as being more than 65 years of age by the world health organization. the increase in the domestic aged population is related to the increasing demand for therapeutic ercp in elderly patients with pancreato-biliary disorders. common bile duct stones and cancer account for70 % of all jaundice cases in patients over the age of 65 years . this is related to increasing prevalences of cholelithiasis, choledocholithiasis, and malignancy with advancing age . endoscopic retrograde cholangiopancreatography(ercp) represents the gold standard technique for the treatment of biliary or pancreatic tract pathology, and it could be often performed with therapeutic intent by realizing procedures such as insertion of bile duct stents and/or endoscopic sphincterotomy. however, evidence about its safety in the elderly is still controversial.

however, therapeutic ercp is an invasive procedure and is associated with several complications, such as bleeding, pancreatitis, cholangitis, perforation, and mortality. a higher incidence of periprocedural complications might be expected in elderly patients because of the high prevalence of concomitant medical disorders, such as cardiopulmonary and cerebrovascular diseases, and the poor general condition of this population \[8\]. despite many previous reports of the safety and efficacy of ercp in elderly patients, in real clinical practice, there is concern regarding complications of ercp performed in patients more than 65years old. also comparative reports of the efficacy and safety of therapeutic ercp, especially inpatients over 65 years of age, are limited. to investigate this issue, we will evaluate the clinical outcomes such as the technical success rate, procedure-related complications rate, and anesthesia-related adverse events rate of therapeutic ercp in a older aged group (over than 65 years of age) and control group (less than 65 years of age) at a single tertiary center. aim of the work this study aims to evaluate the outcome and safety of ercp in patients with obstructive jaundice over than 65 years of age.

Eligibility criteria:
inclusion criteria: * patients with obstructive jaundice older than 18 years old exclusion criteria: * patients who refuse consent * patients under 18 years old
pediatric primary immunodeficiency disease (pid) in china

Conditions: Primary Immunodeficiency Disease

Summary: this study is a prospective cohort study of children diagnosed with primary immunodeficiency disease (pid). the aim is to investigate the clinical characteristics and prognosis of pid in chinese children.

primary immunodeficiency disease (pid) is a group of rare and fatal disease. however, the research about clinical characteristics, treatment, management and prognosis of chinese children with pid is still not perfect and there is no basic and large database. therefore, this study is conducted, in order to set up a complete database and long term follow up of chinese children with pid, and establish foundations for basic research and precise medicine. this study is divided into two parts. in part one, pediatric patients with pid in the past 10 years will be collected retrospectively by review medical records from these centers, and investigate the clinical features and prognosis. in part two, all new cases with suspected pid will be collected. clinical symptoms, physical examination, blood tests, and humoral and cellular immune functions will be detected. gene tests would be done when necessary to confirm the diagnosis. then follow up at 6-moth, 1-year, 2-year, 3-year, 4-year and 5-year respectively. the trial will be completed in 60 months.

Eligibility criteria:
inclusion criteria: 1. age: from neonates to 18 years old 2. fulfilling the one of the followings: 1. severe infection after vaccination (bcg, polio arthritis pill) 2. chronic/recurrent ear infection, sinus infections and respiratory tract infection 3. recurrent, deep skin or deep-seated infections 4. boys with early period and refractory thrombocytopenia 5. infants with obviously decreased absolute number of lymphocytes 6. severe allergy with infection 7. infant diabetes with severe diarrhea 8. boys with severe epstein-barr virus infection 9. infants with hepatosplenomegaly and generalized lymphadenopathy 10. infantile hemophagocytic syndrome 11. failure of an infant to gain weight or grow normally 12. persistent thrush in mouth or fungalinfection on skin 13. family history of primary immunodeficiency 14. invasive pneumococcal infection 15. erythrodermic psoriasis 3. gene test confirmed pid pediatric patients exclusion criteria: subject will be excluded if she or he would not enroll into this study
functional splint for osteoarthritis of the trapeziometacarpal joint

Conditions: Osteoarthritis

Summary: forty participants were enrolled in a randomized, controlled clinical trial to evaluate the effectiveness of a functional thumb splint for trapeziometacarpal oa in the dominant hand.

treatment, randomized, single blind, placebo control, parallel assignment, efficacy study

Eligibility criteria:
inclusion criteria: * clinical and radiological diagnosis of idiopathic grade ii and iii oa of the tmc joint on the dominant hand; * either gender; * over 40 years of age; * pain in the base of the thumb of the dominant hand greater than three and less than or equal to seven on the 0 to 10-cm visual analogue scale (vas) for pain. exclusion criteria: * severe deformities of the dominant hand that did not allow gripping between the first, second and third fingers; * deformities of distal interphalangeal joint; * use of a splint on the thumb in the previous six months; * surgery on the hand under study in the previous six months or scheduled in the upcoming six months; * allergy to the splint material; * incapacity to respond to the questionnaire and perform the tests; * geographic inaccessibility; * injections in the hand under study in the previous six months; * other associated diseases such as carpal tunnel syndrome, fractures in the carpus, tendonitis, chronic inflammatory arthropathy; * alterations in the use of anti-inflammatory medication and analgesics in the previous three months.

Keywords: osteoarthritis thumb splint pain function osteoarthritis of the trapeziometacarpal (tmc) joint
high dose ara-c (hdac) and interleukin-2 (il-2) for patients with acute myelogenous leukemia (aml)

Conditions: Acute Myelogenous Leukemia

Summary: this study will add interleukin-2 (il-2) to a regimen of post-remission therapy consisting of high-dose ara-c. patients with aml in first remission will receive 3 cycles of high-dose ara-c followed by continuous infusion and bolus interleukin-2 (il-2). we, the researchers at the dana-farber cancer institute, plan to evaluate the immunologic effects of such treatment in these patients.

patients will receive standard remission induction therapy with daunorubicin at a dose of 45 mg/m2/day for 3 days and continuous infusion cytarabine at a dose of 200 mg/m2/day for 7 days. those patients who enter a remission status and have preserved liver and kidney function will then receive 3 cycles of post-remission therapy that will consist of high-dose cytarabine at a dose of 3000 mg/m2 every 12 (q12) hours on days 1, 3 and 5 (total of 6 doses). patients who are still in remission will receive interleukin-2 (il-2) upon count recovery at a dose of 8.1 x 10\^5 u/m2/day by continuous infusion for 10 weeks. in addition, patients will receive bolus il-2 at a dose of 6 x 10\^5 u/m2 by intravenous bolus weekly for 6 doses through day 63. patients will be seen on a weekly basis while on treatment for examination and bloodwork. at the end of treatment, patients will have a physical exam and bloodwork performed monthly for two years, then 4 times per year for two years.

Eligibility criteria:
inclusion criteria: * patients must have aml based on french-american-british (fab) criteria. * patients must have a total bilirubin of \< 2.0 mg/dl, sgot \< 90 iu/ml, alkaline phosphatase \< 250 u/ml and a serum creatinine \< 2.0 mg/dl. * age 18 years or greater. exclusion criteria: * history of an antecedent hematologic malignancy such as myelodysplastic syndromes (mds). * uncontrolled infection. * history of a previous or concomitant malignancy other than non-melanoma skin cancer. * evidence of central nervous system (cns) leukemia. * current use of corticosteroids. * prior treatment for aml, other than hydroxyurea.

Keywords: aml acute myelogenous leukemia cytarabine interleukin-2
to evaluate the efficacy and safety of shampoo td03 and td07 in scalp diseases

Conditions: Scalp Dermatitis

Summary: scalp conditions are common chronic skin inflamations with the occurence rate of 1 - 5 % among the population. td03 shampoo and td07 shampoo are widely used to avoid hair loss with successful rate reaching nearly 95%. this trial is going to evaluate the efficacy of getting rid of dandruff as well as the safety of the investigational products in comparison to a reference (ketoconazole 2%) during a 4-week treatment period.

scalp conditions are common chronic skin inflamations with the occurence rate of 1 - 5 % among the population. td03 shampoo and td07 shampoo are widely used to avoid hair loss with successful rate reaching nearly 95%. with herbal ingredients including gleditsia, morus alba, ocimum tenuiflorum, oroxylum indicum, ageratum conyzoides, the investigational products could reduce the severity of inflamation, infection and help to prevent hair loss. this trial is planning to evaluate the efficacy of the ips in terms of inflamation reduction, dandruff reduction on subjects using the ips compared to a reference (ketoconazole 2%). the trial is intended to last for 18 months with subject visits and 3 arms (122 subjects per arm). the first arm receive td3 while td7 is provided to the second arm in comparison to the placebo of the last arm. it will be conducted at national hospital of dermato - venerology, vietnam.

Eligibility criteria:
inclusion criteria: * \> 18 years old and signed the icf. * diagnosed with head skin inflamtion with iga \<= 3. * voluntary sign the icf before any procedures. * no hypersentivity to the ip. exclusion criteria: * use oral antifungal 1 month prior to the trial participation or topical antifungal 2 weeks prior to the trial participation. * suffering chronic or acute diseases that may affect the trial.
inter-regional cohort of neonatal and infant cholestasis in the greater southwest region

Conditions: Cholestasis

Summary: the goal of the study is to characterize the epidemiologic data of the neonatal and infant cholestasis.


Eligibility criteria:
inclusion criteria: * infant \<1 year suffering from cholestasis exclusion criteria: * rejection or inability for parent to give their informed consent

Keywords: cholestasis neonatal infant
initial dosing of bi 655130 in palmoplantar pustulosis patients

Conditions: Psoriasis

Summary: the primary objective of this trial is to investigate the safety and efficacy of bi 655130 in patients with ppp following multiple intravenous administrations compared to placebo.


Eligibility criteria:
inclusion criteria: * male or female patients, 18 to 65 years of age at screening. * palmoplantar pustulosis * further inclusion criteria apply exclusion criteria: * presence or known history of anti- tumor necrosis factor (tnf)-induced palmoplantar pustulosis (ppp)-like disease. * active or latent tuberculosis * further exclusion criteria apply
safety and efficacy of the fruit-based product opal a for the treatment of chronic venous and pressure ulcers

Conditions: Venous Ulcer; Pressure Ulcer

Summary: the purpose of this study is to examine the safety and efficacy of the fruit-based product opal a for the treatment of chronic venous and pressure ulcers.


Eligibility criteria:
inclusion criteria: * male or female. * aged ≥ 18 years. * presence of either: * a venous leg ulcer with a surface area ≥ 2 cm2 and \< 25 cm2 (best estimate of debrided wound), or * a stage ii or iii pressure ulcer (as per australian wound management association \[awma\] definitions) * able to tolerate compression therapy (for venous ulcer group only) * willing and able to provide written informed consent * additional inclusion criterion after four-week standard care run-in period: * a less than or equal to 25% reduction in wound surface area compared with wound surface area at the screening visit exclusion criteria: * another ulcer within 10 cm of the ulcer to be treated * patients with diabetes (fasting blood glucose value ≥ 7 mmol/l or random blood glucose \> 11 mmol/l) that in the opinion of the investigator is uncontrolled * ankle-brachial pressure index of \< 0.8 (participants with venous ulcers only) * alanine transaminase (alt) or aspartate transaminase (ast) levels 3x the upper limit of normal * any dermatologic condition or disorder (with the exception of dermatitis associated with venous stasis) that may interfere with the appropriate assessment and treatment of the participant's ulcer * clinical signs of ulcer infection. * current or recent (within the past two weeks) daily treatment with immunosuppressive medications (including oral corticosteroids; inhaled and topical corticosteroids are permitted; topical agents must not be applied within 10 cm of ulcer wound), cytotoxins or anti-inflammatory agents (intermittent non-steroidal anti-inflammatory agent use is permitted) * known hypersensitivity to paw paw products * pregnancy, planned pregnancy or lactation * participation in another clinical trial within one month of study entry * another disease or condition that in the opinion of the investigator may jeopardize the safety of the participant or their ability to participate in the study * participant previously screened or randomized in this study * cognitive impairment that in the opinion of the investigator leaves the participant incapable of providing informed consent

Keywords: ulcer venous pressure wound treatment
salt and gut study

Conditions: High Blood Pressure

Summary: high sodium intake is a significant risk factor for hypertension. recently, animal studies connect high sodium intake to the gut-immune axis and highlight the gut microbiome as a potential therapeutic target to counteract salt-sensitive conditions and hypertension. the objective of this project is to determine the effects of high salt intake on gut microbiota composition and gut intestine barrier integrity, leading to increased bp in humans. the investigators also hypothesize that high salt intake affects the gut microbiome in a sex-specific manner. in this pilot study, the investigators also test whether telehealth or in-person nutritional coaching help to decrease dietary sodium intake and improve diet quality

the investigators will conduct a randomized, double-blind, placebo-controlled trial in normotensive and stage 1 hypertensive drug naïve participants (age 18-50 years, equal distribution of blacks and whites, and males and females, bp \<140/90 mmhg). the average intake of sodium in the american diet is 3,400 mg per day. the average recommended dose is 2,300 mg per day. eligible participants will be enrolled and provided with one-hour in-person/telehealth nutritional counseling at the gpi to reduce their sodium intake by 1,100 mg per day to achieve the sodium intake of 2,300 mg/day. participants will then be randomized to receive either placebo or salt pills of 2,000 mg per day for four weeks while continuously receiving weekly telehealth nutritional counseling. the salt group's sodium intake will be 4,300 mg per day, while the sodium intake in the placebo group will be 2,300 mg per day. participants will have a follow-up visit at six months after the 4-week sodium intervention. participants will be tested four times (figure 1). participants will receive the first 1-hour in-person/telehealth nutrition counseling at gpi (baseline) and three weekly telehealth nutrition counseling during the 4-week intervention period.

Eligibility criteria:
inclusion criteria: * aged between 18-50 years * african americans (aas) or european americans (eas) * bp \<140/90 mmhg * not on any prescription medications * normal kidney function (egfr ≥ 90 ml/min/1.73 m2) exclusion criteria: * pregnant or nursing * previous diagnosis of major cardiovascular diseases including myocardial infarction, congestive heart failure or stroke, diabetes, autoimmune, chronic liver and kidney disease * previous diagnosis of crohn's disease or any other intestinal conditions * previous diagnosis of major lung diseases such as chronic obstructive pulmonary disease (copd) * previous diagnosis of cancer * alcohol and drug abuse.